New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
08:45 EDTINSYInsys Therapeutics price target raised to $99 from $50 at JMP Securities
JMP Securities increased its price target on Insys after the company reported higher than expected earnings. The firm expects the company to benefit from continued growth in its Subsys drug and further advances in its pipeline. JMP Securities reiterates an Outperform rating on the stock.
News For INSY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
08:11 EDTINSYInsys Therapeutics receives FDA ODD for LEP candidate
Insys Therapeutics announced that the FDA has granted orphan drug designation, or ODD, to its Liposomal Encapsulated Paclitaxel, or LEP, candidate for the treatment of ovarian cancer.
January 22, 2015
11:05 EDTINSYInsys Therapeutics granted orphan status for ovarian cancer treatment
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use